Lighthouse Investment Partners LLC Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Lighthouse Investment Partners LLC acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,500 shares of the specialty pharmaceutical company's stock, valued at approximately $3,017,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Focus Partners Wealth bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $551,000. Frontier Capital Management Co. LLC grew its stake in Jazz Pharmaceuticals by 46.0% in the 4th quarter. Frontier Capital Management Co. LLC now owns 35,002 shares of the specialty pharmaceutical company's stock valued at $4,310,000 after buying an additional 11,027 shares in the last quarter. Deutsche Bank AG raised its holdings in Jazz Pharmaceuticals by 4.0% during the 4th quarter. Deutsche Bank AG now owns 16,012 shares of the specialty pharmaceutical company's stock valued at $1,972,000 after acquiring an additional 609 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in Jazz Pharmaceuticals by 16.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 302,109 shares of the specialty pharmaceutical company's stock valued at $37,205,000 after acquiring an additional 43,710 shares during the period. Finally, Dean Capital Management lifted its position in shares of Jazz Pharmaceuticals by 15.0% during the fourth quarter. Dean Capital Management now owns 16,126 shares of the specialty pharmaceutical company's stock worth $1,986,000 after acquiring an additional 2,108 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares in the company, valued at $1,189,587.54. This represents a 36.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. This trade represents a 10.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,236 shares of company stock worth $3,956,190 over the last ninety days. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Price Performance

JAZZ traded down $0.31 during trading on Monday, reaching $108.67. The stock had a trading volume of 139,480 shares, compared to its average volume of 843,195. The business has a 50-day moving average of $115.73 and a 200-day moving average of $122.09. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market cap of $6.70 billion, a PE ratio of 15.30, a PEG ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.68 earnings per share. As a group, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Analyst Ratings Changes

JAZZ has been the subject of several recent research reports. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Truist Financial upped their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.